FDA and Centocor post Remicade warning

08/25/2004 | MSNBC

The agency and the manufacturer are warning of instances of fatal blood and central nervous system disorders associated with taking Remicade, a drug used for rheumatoid arthritis and Crohn's disease. Centocor, a Johnson & Johnson subsidiary, worked with the FDA to revise its label for the drug and warned doctors in a letter to use caution in giving Remicade to patients with histories of significant blood abnormalities.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ